RBC
AGN

Roble Belko & Company’s Allergan plc AGN Stock Holding History

Roble Belko & Company’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-48
Closed -$11K – 362
2017
Q1 		$11K Hold
48
– – 0.01% 191
2016
Q4 		$10K Buy
48
+40
+500% +$8.29K 0.01% 209
2016
Q3 		$2K Sell
8
-62
-89% -$15.2K ﹤0.01% 281
2016
Q2 		$16K Buy
+70
New +$16.1K 0.01% 168

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Roble Belko & Company's AGN Position: Q2 2017 in Review

Roble Belko & Company sold out of Allergan plc (AGN) in Q2 2017, closing a stake of 48 shares — an estimated $11K sold.

Roble Belko & Company first reported a position in AGN in Q2 2016 and held it in 4 quarters. The position peaked at $16K in Q2 2016. 1,115 funds tracked by Wall St. Rank hold AGN as of Q2 2017.

  • Roble Belko & Company reported no remaining Allergan plc position as of Q2 2017 after selling out during the quarter.
  • Roble Belko & Company sold 48 Allergan plc shares in Q2 2017, an estimated $11K.
  • Roble Belko & Company first reported a position in Allergan plc in Q2 2016 and held it in 4 quarters.
  • Roble Belko & Company's Allergan plc position peaked at $16K in Q2 2016.
  • 1,115 funds tracked by Wall St. Rank held Allergan plc as of Q2 2017.

Based on Roble Belko & Company's 13F filing for Q2 2017, filed 11 Aug 2017.